Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
59.17
+0.20 (0.34%)
At close: Apr 25, 2025, 4:00 PM
59.25
+0.08 (0.14%)
After-hours: Apr 25, 2025, 5:13 PM EDT
Incyte Revenue
In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth. Incyte had revenue of $1.18B in the quarter ending December 31, 2024, with 16.32% growth.
Revenue (ttm)
$4.24B
Revenue Growth
+14.76%
P/S Ratio
2.89
Revenue / Employee
$1,620,641
Employees
2,617
Market Cap
11.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
INCY News
- 2 days ago - Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire
- 4 days ago - Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
- 17 days ago - Incyte to Report First Quarter Financial Results - Business Wire
- 20 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - These 20 worst-performing stocks in the S&P 500 sank 17% or more in March - Market Watch
- 4 weeks ago - Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico - GlobeNewsWire
- 5 weeks ago - Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib - Seeking Alpha
- 5 weeks ago - Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - Investopedia